Business Models for Personalized Medicine:

Marrying Molecular Diagnostics and Therapeutics

The Personalized Medicine Coalition invites you to an exclusive seminar and workshop exploring the business models that underpin personalized medicine. Join a panel of pharmaceutical, biotechnology, diagnostic and health policy experts as we discuss the promise of - and barriers to - the co-development of diagnostic and therapeutic products in an effort to better understand the exigencies of personalized medicine and to suggest ideas to help advance it.

Guest Panelists will include:
Diagnostics
Brad Margus, CEO, Perlegen
Randy Scott, CEO, Genomic Health
Bill Young, CEO, Monogram Biosciences


Pharmaceutical and Biotech
Kenneth Hillan, VP, Development Sciences,
    Genentech
Ilya Oshman, VP & General Manager,     Strategic Investments Group, Pfizer
Bert vandenBergh, Vice President,
    Customer Solutions, Eli Lilly

Academic
Kathryn Phillips, University of California,
    San Francisco


Moderator:
Michael Goldberg, General Partner, MDV

Topics to include:

• Notable successes and failures from close Dx/Rx connections
• "Rate-limiting" obstacles that impede cooperation between pharmaceutical and diagnostic companies, such as cultural biases, economic assumptions, and concerns about Intellectual Property
• Business models that are driving personalized medicine today
• Public policy initiatives that could encourage/stimulate the co-development of molecular diagnostics and therapeutics

PMC's West Coast Networking Reception and Dinner

Keynote Speaker:
Brook Byers, Partner, Kleiner Perkins
    Caufield & Byers

The Personalized Medicine Coalition, representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information please visit www.personalizedmedicinecoalition.org.